For Rhode Island's publicly traded companies, recovery mixed after tariffs
June 26, 2025: $68.14
June 27, 2024: $58.36
⬆️ 16.8 percent
Market cap: $86.2 billion
Textron
June 26, 2025: $80.26
June 27, 2024: $86.34
⬇️ 7 percent
Market cap: $14.5 billion
Hasbro
June 26, 2025: $72.31
June 27, 2024: $58.16
⬆️ 24.3 percent
Market cap: $10.1 billion
Citizens Bank
June 26, 2025: $44.12
June 27, 2024: $34.63
⬆️ 27.4 percent
Market cap: $19.1 billion
Washington Trust
June 26, 2025: $28.17
June 27, 2024: $26.51
⬆️ 6.3 percent
Advertisement
Market cap: $543.4 million
United Natural Foods
June 26, 2025: $21.48
June 27, 2024: $12.90
⬆️ 66.5 percent
Market cap: $1.3 billion
Bally's
June 26, 2025: $9.96
Nov. 21, 2024: $22.07*
⬇️ 54.87 percent
Market cap: $488.2 million
*Bally's stockholders approved a merger agreement with an affiliate of Standard General L.P. in November 2024.
AstroNova
June 26, 2025: $9.28
June 27, 2024: $15.15
⬇️ 38.75 percent
Market cap: $70.5 million
This story first appeared in Rhode Map, our free newsletter about Rhode Island that also contains information about local events, links to interesting stories, and more. If you'd like to receive it via email Monday through Friday,
.
Dan McGowan can be reached at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Here's What to Expect From Textron's Next Earnings Report
Providence, Rhode Island-based Textron Inc. (TXT) operates in the aircraft, defense, industrial, and finance businesses worldwide. With a market cap of $14.8 billion, the company operates in six segments: Textron Aviation, Bell, Textron Systems, Industrial, Textron eAviation, and Finance. The company is set to unveil its second-quarter results on Thursday, July 24, before the market opens. Ahead of the event, analysts expect TXT to report non-GAAP earnings of $1.44 per share, down 6.5% from the profit of $1.54 per share reported in the year-ago quarter. Additionally, the company has surpassed the Street's bottom-line projections in three of the past four quarters, while missing on one occasion. UnitedHealth Stock Is One of the Worst-Performing S&P 500 Stocks in 2025. Should You Buy the Dip? AI Isn't Just About Nvidia: 2 Rising Stars in the Artificial Intelligence Race 'It's a Miracle': Nvidia CEO Says Their New Technology Takes 'AI Supercomputing to a Whole New Level' Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the current year, its earnings are expected to come in at $6.12 per share, up 11.7% from $5.48 per share reported in the year-ago quarter. Moreover, in fiscal 2026, its earnings are expected to rise 9.5% year-over-year to $6.70 per share. TXT stock has declined 4.6% over the past 52 weeks, underperforming the Industrial Select Sector SPDR Fund's (XLI) 22.8% surge and the S&P 500 Index's ($SPX) 13.4% uptick during the same time frame. TXT stock rose 2.6% following the release of its Q1 earnings on Apr. 24. The company's revenue increased 5.5% year-over-year to $3.3 billion and surpassed the Wall Street estimates, mainly driven by a robust growth in its Bell segment. Additionally, the company's adjusted EPS rose 6.7% year-over-year to $1.28 and surpassed the consensus estimates by 9.4%. The consensus opinion on TXT is somewhat optimistic, with a 'Moderate Buy' rating overall. Of the 14 analysts covering the stock, opinions include six 'Strong Buys,' seven 'Holds,' and one 'Strong Sell.' Its mean price target of $85.50 suggests a 4% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
3 days ago
- Yahoo
Bally's (BALY): Buy, Sell, or Hold Post Q1 Earnings?
Bally's stock price has taken a beating over the past six months, shedding 38.7% of its value and falling to $11.34 per share. This may have investors wondering how to approach the situation. Is there a buying opportunity in Bally's, or does it present a risk to your portfolio? Get the full breakdown from our expert analysts, it's free. Even with the cheaper entry price, we're sitting this one out for now. Here are three reasons why you should be careful with BALY and a stock we'd rather own. Long-term growth is the most important, but within consumer discretionary, product cycles are short and revenue can be hit-driven due to rapidly changing trends and consumer preferences. Bally's recent performance shows its demand has slowed significantly as its annualized revenue growth of 2.9% over the last two years was well below its five-year trend. Note that COVID hurt Bally's business in 2020 and part of 2021, and it bounced back in a big way thereafter. A company's ROIC, or return on invested capital, shows how much operating profit it makes compared to the money it has raised (debt and equity). We like to invest in businesses with high returns, but the trend in a company's ROIC is what often surprises the market and moves the stock price. Unfortunately, Bally's ROIC has decreased over the last few years. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between. As long-term investors, the risk we care about most is the permanent loss of capital, which can happen when a company goes bankrupt or raises money from a disadvantaged position. This is separate from short-term stock price volatility, something we are much less bothered by. Bally's burned through $113.5 million of cash over the last year, and its $5.55 billion of debt exceeds the $264.7 million of cash on its balance sheet. This is a deal breaker for us because indebted loss-making companies spell trouble. Unless the Bally's fundamentals change quickly, it might find itself in a position where it must raise capital from investors to continue operating. Whether that would be favorable is unclear because dilution is a headwind for shareholder returns. We remain cautious of Bally's until it generates consistent free cash flow or any of its announced financing plans materialize on its balance sheet. We see the value of companies helping consumers, but in the case of Bally's, we're out. Following the recent decline, the stock trades at 2.1× forward EV-to-EBITDA (or $11.34 per share). While this valuation is optically cheap, the potential downside is huge given its shaky fundamentals. There are better stocks to buy right now. We'd recommend looking at the most entrenched endpoint security platform on the market. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. 登入存取你的投資組合
Yahoo
3 days ago
- Yahoo
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CVS Health (CVS), which belongs to the Zacks Medical Services industry. When looking at the last two reports, this drugstore chain and pharmacy benefits manager has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 32.64%, on average, in the last two quarters. For the last reported quarter, CVS Health came out with earnings of $2.25 per share versus the Zacks Consensus Estimate of $1.71 per share, representing a surprise of 31.58%. For the previous quarter, the company was expected to post earnings of $0.89 per share and it actually produced earnings of $1.19 per share, delivering a surprise of 33.71%. Thanks in part to this history, there has been a favorable change in earnings estimates for CVS Health lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. CVS Health has an Earnings ESP of +6.35% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on July 31, 2025. With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss. Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
